Ken Griffin Navidea Biopharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.24 - $0.34 $6,730 - $9,534	-28,042 Reduced 29.88%	65,807 $17,000
Q4 2022 Feb 14, 2023	BUY	$0.18 - $0.3 $16,892 - $28,154	93,849 New	93,849 $19,000
Q2 2022 Aug 15, 2022	BUY	$0.63 - $1.1 $4,192 - $7,320	6,655 Added 37.89%	24,217 $17,000
Q1 2022 May 16, 2022	SELL	$0.72 - $1.2 $29,520 - $49,200	-41,000 Reduced 70.01%	17,562 $14,000
Q4 2021 Feb 14, 2022	BUY	$1.0 - $1.82 $16,425 - $29,893	16,425 Added 38.98%	58,562 $58,000
Q3 2021 Nov 15, 2021	SELL	$1.53 - $1.85 $34,434 - $41,636	-22,506 Reduced 34.82%	42,137 $74,000
Q2 2021 Aug 16, 2021	BUY	$1.55 - $2.15 $15,699 - $21,777	10,129 Added 18.58%	64,643 $118,000
Q1 2021 May 17, 2021	BUY	$1.99 - $2.9 $74,065 - $107,935	37,219 Added 215.2%	54,514 $110,000
Q4 2020 Feb 16, 2021	SELL	$1.88 - $2.84 $17,290 - $26,119	-9,197 Reduced 34.72%	17,295 $37,000
Q3 2020 Nov 16, 2020	SELL	$2.69 - $4.95 $11,045 - $20,324	-4,106 Reduced 13.42%	26,492 $72,000
Q2 2020 Aug 14, 2020	BUY	$0.7 - $4.16 $1,729 - $10,279	2,471 Added 8.79%	30,598 $121,000
Q1 2020 May 15, 2020	BUY	$0.76 - $1.54 $21,376 - $43,315	28,127 New	28,127 $21,000
Q4 2019 Feb 14, 2020	SELL	$0.65 - $1.26 $18,794 - $36,432	-28,915 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$0.5 - $0.91 $6,073 - $11,052	12,146 Added 72.43%	28,915 $19,000
Q2 2019 Aug 14, 2019	BUY	$0.62 - $3.6 $10,396 - $60,368	16,769 New	16,769 $11,000

10.4K

Ticker NAVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,150,900
Description
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.